Home
Request Uromonitor
Press
Contact us
Login
English
- English
- Português
- Español
- Français
- Deutsch

Promotional UroMonitor

January 31, 2018

|In Business

|By uromonitor

Prev
Next

PRESS

IN TIMES OF COVID19, CANCER PATIENTS HAVE A NEW WAY TO AVOID DELAYING DIAGNOSTIC PROCEDURES AND SURVEILLANCE OF BLADDER TUMOURS. May 21, 2020
TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients February 5, 2020
Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review February 5, 2020
Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study February 5, 2020
Uromonitor as a Novel Sensitive and Specific Urine-based Test for Recurrence Surveillance of Patients with Non-muscle Invasive Bladder Cancer – Article in URO Today October 6, 2018

Choose a language

VALUE PROPOSITION

“For persons at risk or patients diagnosed with bladder cancer, as well as their urologist, who have the need of more convenient surveillance methods, Uromonitor is a completely non-invasive, urine-based, In vitro Diagnosis (IVD) kit that is able to detect bladder cancer with high sensitivity and specificity.

Uromonitor is easy and can deliver reliable results to reducecostswithfollow-up”.